Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Resistance testing for the treatment of chronic hepatitis C with direct acting antivirals: when and for how long?

1 Mar 2017

Abstract excerpt

The need to test for resistance associated substitutions (RAS) has been intensively debated in the past two years. In the absence of pangenotypic combinations, it seems reasonable that, if available, RAS testing in the NS5A gene at baseline for genotypes 1a and 3 may help to avoid overtreatment in terms of ribavirin usage and/or prolonged treatment duration. When patients fail treatment, RAS testing may also be...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hepatitis B Virus Studies
Share to Hepatitis C virus research
Share to Liver Disease Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28331841
DOI: 10.18683/germs.2017.1107

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Resistance testing for the treatment of chronic hepatitis C with direct acting antivirals: when and for how long?PMID 28331841Read ↗

The Role of RASs /RVs in the Current Management of HCV.Semantic proximity Read ↗

Prevalence of Drug Resistance Associated Substitutions in Persons With Chronic Hepatitis C Infection and Virological Failure Following Initial or Re-treatment With Pan-genotypic Direct-Acting Antivirals: A Systematic Review and Meta-analysis.Semantic proximity Read ↗

Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018.Semantic proximity Read ↗

Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use.Semantic proximity Read ↗

Resistance to direct antiviral agents in patients with hepatitis C virus infection.Semantic proximity Read ↗

Resistance Associated Mutations in HCV Patients Failing DAA Treatment.Semantic proximity Read ↗

Prevalence of NS5A resistance associated substitutions in patients with hepatitis C virus genotypes 1a and 3: Impact on current therapeutic strategies.Semantic proximity Read ↗

NS5A Resistance: Clinical Implications and Treatment Possibilities.Semantic proximity Read ↗

Resistance to direct-acting antiviral agents: clinical utility and significance.Semantic proximity Read ↗

Update on hepatitis C virus resistance to direct-acting antiviral agents.Semantic proximity Read ↗

Baseline NS5A resistance associated substitutions may impair DAA response in real-world hepatitis C patients.Semantic proximity Read ↗

Hepatitis C virus resistance to the new direct-acting antiviralsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.